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Key Points
Question
What is the incidence of hospital-onset Clostridium difficile infection (CDI) and its associated length of
stay?
Findings
This systematic review and meta-analysis of 13 studies using patient-days as the denominator found that
the incidence of hospital-onset CDI was 8.3 cases per 10 000 patient-days. Among propensity score–
matched studies of the length of stay, the mean difference in length of stay between patients with and those
without CDI varied from 3.0 to 21.6 days.
Meaning
Pooled estimates from currently available literature suggest that CDI is associated with a large burden on
the US health care system.
Abstract
Importance
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An understanding of the incidence and outcomes of Clostridium difficile infection (CDI) in the United
States can inform investments in prevention and treatment interventions.
Objective
To quantify the incidence of CDI and its associated hospital length of stay (LOS) in the United States using
a systematic literature review and meta-analysis.
Data Sources
MEDLINE via Ovid, Cochrane Library Databases via Wiley, Cumulative Index of Nursing and Allied
Health Complete via EBSCO Information Services, Scopus, and Web of Science were searched for studies
published in the United States between 2000 and 2019 that evaluated CDI and its associated LOS.
Study Selection
Incidence data were collected only from multicenter studies that had at least 5 sites. The LOS studies were
included only if they assessed postinfection LOS or used methods accounting for time to infection using a
multistate model or compared propensity score–matched patients with CDI with control patients without
CDI. Long-term-care facility studies were excluded. Of the 119 full-text articles, 86 studies (72.3%) met
the selection criteria.
Data Extraction and Synthesis
Two independent reviewers performed the data abstraction and quality assessment. Incidence data were
pooled only when the denominators used the same units (eg, patient-days). These data were pooled by
summing the number of hospital-onset CDI incident cases and the denominators across studies. Random-
effects models were used to obtain pooled mean differences. Heterogeneity was assessed using the I  value.
Data analysis was performed in February 2019.
Main Outcomes and Measures
Incidence of CDI and CDI-associated hospital LOS in the United States.
Results
When the 13 studies that evaluated incidence data in patient-days due to hospital-onset CDI were pooled,
the CDI incidence rate was 8.3 cases per 10 000 patient-days. Among propensity score–matched studies (16
of 20 studies), the CDI-associated mean difference in LOS (in days) between patients with and without CDI
varied from 3.0 days (95% CI, 1.44-4.63 days) to 21.6 days (95% CI, 19.29-23.90 days).
Conclusions and Relevance
Pooled estimates from currently available literature suggest that CDI is associated with a large burden on
the health care system. However, these estimates should be interpreted with caution because higher-quality
studies should be completed to guide future evaluations of CDI prevention and treatment interventions.
Introduction
Clostridium difficile (also known as Clostridioides difficile) is the most common pathogen causing health
care–associated infections in the United States, accounting for 15% of all such infections.  A Centers for
Disease Control and Prevention report on antibiotic resistance threats categorized C difficile as an urgent
threat.  Antibiotic treatment for C difficile infection (CDI) is often followed by recurrent infection, leading
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to nontraditional treatments, such as fecal transplant and oral administration of nontoxigenic C difficile
spores.
Information about the burden of CDI in the United States could inform investments in prevention and
treatment interventions. This information should include the incidence of CDI, how this incidence has
changed over time, and poor outcomes associated with CDI. Although prior studies have shown that CDI is
associated with poor outcomes, such as recurrence, long hospital length of stay (LOS), mortality, and high
treatment costs, these results vary by study location and patient population.  In addition, many current
estimates of the poor outcomes and costs associated with CDI do not take into account the underlying
severity of illness among patients who develop CDI and may overestimate the true attributable outcomes.
To address gaps in our understanding of the current burden associated with CDI in the United States, we
conducted a systematic literature review of studies conducted in the United States and published after 2000
that evaluated the incidence of CDI and associated LOS. The goals were to describe the recent incidence of
CDI and to evaluate LOS attributable to CDI.
Methods
Search Strategy
This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA)  and Meta-analysis of Observational Studies in
Epidemiology (MOOSE)  reporting guidelines. An experienced health sciences librarian (A.B.) conducted
systematic searches in MEDLINE via Ovid, Cochrane Library Databases via Wiley, Cumulative Index of
Nursing and Allied Health Complete via EBSCO Information Services, Scopus, and Web of Science to
identify articles published from the inception of the database to February 2019. Citations published before
2000 were excluded. A combination of keywords and subject headings were used for “Clostridium
difficile,” “length of stay,” and “incidence.” The full search strategies can be found in eAppendix 1 in the
Supplement.
Inclusion and Exclusion Criteria
Publications were included if they evaluated the incidence of CDI or LOS associated with CDI. Studies
were excluded if they did not contain original data, did not have a control group, were published outside the
United States, were published in a language other than English, or were published before 2000. The year
2000 was chosen as the beginning of this systematic literature review because that was when the epidemic
BI/NAP1/027 strain of C difficile emerged, after which CDI increased in prevalence and became less
responsive to treatment.  We excluded studies if they assessed only a specific subset of patients, unless that
population could be categorized as 1 of the following subsets: immunocompromised patients, patients in
the intensive care unit, patients with cancer, patients with end-stage renal disease, patients undergoing
hemodialysis, surgical patients, solid-organ transplant recipients, patients with high-risk gastrointestinal
conditions, or peripartum women. We excluded studies with a study period of less than 1 year. We also
excluded studies of long-term care facilities. Incidence data were collected only from multicenter studies
that had at least 5 sites, because single-site or small studies may be biased by outbreaks or other local
conditions. We included incidence studies with denominators of patient-days or person-years, known
timing of the CDI such as after surgery or after admission (ie, hospital onset [HO]), or exclusion of patients
with a history of CDI.
Studies were included in the LOS analysis only if they provided data on postinfection LOS, if they used
methods accounting for time to infection using a multistate model, or if propensity score–matched patients
with CDI were compared with uninfected controls.  Studies were excluded if they did not have an
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uninfected control group or a denominator that included patients without CDI.
Data Extraction and Quality Assessment
Titles and abstracts of all articles were screened to assess inclusion criteria. Two of 9 independent
reviewers (M.L.S., M.A.W., M.F.K., H.-Y.C., M.L.C., L.A.H., D.J.D., A.R.M., and E.N.P.) abstracted data
for each article. Reviewers resolved disagreements by consensus.
The reviewers abstracted data on study design, study population, setting and years, inclusion and exclusion
criteria, number of patients included, description of control group, definition of CDI, outcomes (eg,
incidence and LOS), and an assessment of the potential risk of bias. Risk of bias was assessed using the
Downs and Black scale.  Reviewers followed all questions from this scale as written except for question
27 (a single item on the Power subscale, which was scored 0-5), which was changed to a yes or no. Two of
us (A.R.M. and M.L.S.) performed component quality analysis independently, reviewed all inconsistent
assessments, and resolved disagreements by consensus.
Statistical Analysis
Data analysis was performed in February 2019. Excel spreadsheet software version 2007 (Microsoft Corp)
and RevMan statistical software version 5.3 (Cochrane Community) were used for statistical analysis.
Incidence data were pooled only when the denominators used the same units (eg, patient-days). These data
were pooled by summing the number of HO-CDI incident cases and the denominators across studies.
Pooled incidence was reported as the number of incident cases per the given denominator (eg, 10 000
patient-days).  No P values were calculated.
Results
Of the 34 775 articles identified (Figure), 119 were full-text articles, and 86 (72.3%) of those articles met
the selection criteria and were included in the systematic literature
review.
 Among these, 66 articles evaluated
incidence,
 and 20 articles evaluated
LOS.  One-fifth of the studies that assessed LOS (4
studies)  scored 18 or more points of the 28 points possible on the Downs and Black scale  and,
thus, were considered to be of higher quality.
Incidence of CDI Calculated Using Patient-Days (13 Studies)
Sixty-six
studies
 measured CDI incidence.
Thirteen of those 66 studies  used patient-days as the denominator (
Table 1). Among these studies, the CDI incidence varied from 2.8 CDI cases per 10 000 patient-days  to
15.8 CDI cases per 10 000 patient-days.  Three studies  were conducted by the Centers for Disease
Control and Prevention. Three studies  were done in New York State. One study  from Southern
California found that the incidence of community-onset, health care facility (HCF)–associated CDI (11.1
cases per 10 000 patient-days) was almost 2-fold higher than that for HO, HCF-associated CDI (6.8 cases
per 10 000 patient-days). The pooled incidence of HO-CDI among the 13
studies  (Table 1) that used patient-days as the denominator was 8.3 CDI
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cases per 10 000 patient-days. Four studies  included more than 100 facilities.
The definitions of C difficile used to identify cases varied. Three studies  used clinical findings and
results of laboratory tests for C difficile, 3 studies  used the Centers for Disease Control and
Prevention surveillance definition to identify C difficile, 2 studies  applied infection preventionist
evaluations for C difficile surveillance, and 2 studies  used only results of laboratory tests for C
difficile. The remaining studies used a variety of ways to identify CDI, including International
Classification of Diseases, Ninth Revision (ICD-9) codes or other billing codes,  laboratory test
results,  clinical findings,  and initial doses of C difficile antibiotic therapy.  When we
examined incidence by time period, we found that the early studies from 2000 to 2008 had a range from 2.8
to 12.2 CDI cases per 10 000 patient-days, studies from 2008 to 2009 had a range from 6.3 to 9.6 CDI cases
per 10 000 patient-days, and the later studies after 2010 reported a range from 6.8 to 15.8 CDI cases per 10 
000 patient-days (Table 1).
Incidence of CDI Calculated Using Person-Years (17 Studies)
Fourteen studies  included both inpatients and outpatients (Table 2),
reflected in a denominator of person-years in 8 studies.  Seven of those 14
studies  used only ICD-9 codes to define CDI. In a study  of adult and adolescent
patients with HIV/AIDS that included more than 100 hospitals, during 10 years of study, the peak incidence
of CDI was 9.59 cases per 1000 person-years among patients with clinical AIDS. A study  of the Armed
Forces Health Surveillance Center in Maryland over the course of 12 years found the incidence of
community-associated CDI to be 5.5 cases per 100 000 person-years. In a study  evaluating the annual
incidence of CDI and multiply recurrent CDI per 1000 person-years, the incidences increased by 42.7%
and 188.8%, respectively, during a decade (2001-2012) in the United States. In another study  with 12
years of data from 5 administrative databases, elderly people (ie, aged >65 years) had a CDI rate of 677
cases per 100 000 person-years. In contrast, a managed-care organization in Colorado found that the CDI
incidence in 2007 was 14.9 CDI cases per 10 000 patient-years.  These studies were too diverse to pool
together into 1 estimate.
Three studies  included only inpatients (Table 2). Two of these studies  assessed the Agency for
Healthcare Research and Quality (AHRQ) National Inpatient Sample (NIS). One evaluated infant patients
from the AHRQ NIS cohort,  and the other study evaluated adult patients from the AHRQ NIS cohort.
Both studies documented substantial increases in CDI incidence between 2000 and 2005, from 2.8 to 5.1
cases per 10 000 hospitalizations, and from 5.5 to 11.2 cases per 10 000 hospitalizations, respectively.
The third study,  which was from the US National Hospital Discharge Survey between 2001 and 2010,
found that the incidence of CDI in the pediatric population was 1.2 CDI discharges per 1000 total
discharges.
Incident Cases of CDI (36 Studies)
Twenty-six studies  documented HO-
CDIs, which we assumed were incident cases (Table 3). Of these studies, the AHRQ NIS was the main data
set, represented by 10 included studies.  These studies assessed diverse patient
populations with different comorbidities, including peripartum women  and patients with inflammatory
bowel disease,  lymphoma,  leukemia,  subarachnoid hemorrhage treated with microsurgical or
endovascular aneurysm repair,  chronic liver disease,  hematopoietic stem cell transplant,
megacolon,  or heart failure.  Thus, the results of these studies were also too diverse to pool together.
One study  found that the CDI incidence among peripartum women increased from 0.36 cases per 10 000
in 1998 to 0.70 cases per 10 000 in 2006. The US National Hospital Discharge Survey database was
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represented in 6 included studies.  These studies also assessed diverse patient populations,
including children  and adults with different comorbidities, such as cancer  and inflammatory bowel
disease.  In 1 of these studies,  the overall incidence of HO-CDI was 369.8 cases per 10 000
hospitalizations for inflammatory bowel disease. In that same study,  the HO-CDI incidence was 445.6
cases per 10 000 hospitalizations for ulcerative colitis and 220.3 cases per 10 000 hospitalizations for Crohn
disease.
Ten studies  evaluated surgical patients (Table 3), and, thus, we assumed that the
CDI cases were incident cases. Five studies  used data from AHRQ NIS. These AHRQ NIS
studies analyzed a variety of surgical procedures, including spine surgery ; hip,  knee,  or lower-
extremity  arthroplasty; and elective colon resections.  One of them had CDI occurring in 1.4% of
patients, for a rate of 144.99 cases of C difficile colitis per 10 000 elective colon resections, and the
incidence increased from 1.31% in 2004 to 1.67% in 2006.
LOS Associated With CDI (20 Studies)
Twenty studies  (Table 4) evaluated CDI-associated LOS.
Sixteen studies  used propensity score matching to evaluate LOS
associated with CDI, 2 studies  used postinfection LOS, 1 study  matched on LOS from admission
until either positive C difficile test results or discharge, and 1 study  accounted for time to infection using
a multistate model. Also, one of the propensity score matched–studies applied multistate modeling to
account for timing of infection.  Pediatric patients were included in 3 of these studies.
Among the 13 propensity score–matched studies of adults, the CDI-associated mean difference in LOS (in
days) between patients with CDI and patients who did not have CDI varied greatly from 3.0 days (95% CI,
1.44-4.63 days)  to 10.3 days.  Among the 3 pediatric propensity score–matched studies,  the
highest CDI-associated mean difference in LOS (in days) was 21.6 days (95% CI, 19.29-23.90 days).
Among the studies that used multistate models to account for timing of infection, a study  performed in
the Veterans Affairs health care system found that the magnitude of its estimated impact was smaller when
methods were used to account for the time-varying nature of infection. That study estimated a CDI-
attributable LOS of only 2.27 days (95% CI, 2.14-2.40 days).  The other study  that performed
propensity score matching and used a multistate model converged on similar excess LOS estimates of 3.1
days (95% CI, 1.7-4.4 days) and 3.3 days (95% CI, 2.6-4.0 days), respectively.
Four studies  that evaluated LOS earned 18 or more points on the Downs and Black scale.  One
study  also used multistate modeling. Another was also performed in the Veterans Affairs health care
system  and found a mean difference between patients with and without CDI of 7.5 days.  One
study  of pediatric patients found that those with CDI had a longer LOS (adjusted odds ratio, 4.34; 95%
CI, 3.97-4.83). Another study  of adult patients in Pennsylvania hospitals showed an attributable hospital
LOS difference of 2.4 days (95% CI, 0.7-4.4 days; P < .01) between patients with and without CDI.
Discussion
National epidemiological investigations have demonstrated recent marked increases in CDI in the United
States.  Thus, a national public health response to this increase requires current estimates of the CDI
incidence.  Our systematic review of the literature found that the CDI incidence varied by study and
that the investigators used different denominators when they calculated the incidence for specific study
populations. In our meta-analysis of studies that used patient-days as the denominator, we estimated the
incidence of CDI in the United States to be 8.3 CDI cases per 10 000 patient-days.
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Variation in CDI incidence may be due, in part, to advances in diagnostic technology and variations in
diagnostic practices.  Nucleic acid amplification tests are more sensitive than traditional C difficile
stool tests (eg, toxin enzyme immunoassay). Nucleic acid amplification tests have been used more
frequently in clinical practice since 2009, when the first commercial polymerase chain reaction was
approved by the US Food and Drug Administration.  The topic of CDI testing methods and risk
adjustment is complex.  Concerns have been expressed about the adequacy of risk adjustment to
account for different CDI testing methods (toxin enzyme immunoassay alone, polymerase chain reaction
alone, toxin enzyme immunoassay plus glutamate dehydrogenase followed by polymerase chain reaction
for discrepancies, polymerase chain reaction followed by toxin enzyme immunoassay, and other diagnostic
options) across HCFs. The choice of testing methods substantially affects the performance of these testing
algorithms.
In addition, the CDI incidence found by these studies likely varied because of the different database
structures adopted by the various
hospitals.
 Some analyses were based on
health care systems databases, but most used large infection control surveillance, state, or national
discharge databases.  Beginning in January 2013, the Centers for
Medicare & Medicaid Services began requiring public reporting of CDI rates via the National Healthcare
Safety Network for those hospitals participating in the Inpatient Prospective Payment System.
Specifically, 1 study  demonstrated an increase in the annual incidence of CDI and multiply recurrent CDI
per 1000 person-years by 42.7% and 188.8%, respectively, between 2001 and 2012. Another CDI
surveillance study  in 7 US states reported an increase not only in community-associated CDI incidence
rates but also an increase in health care–associated CDI incidence rates. Furthermore, CDI can complicate
comorbid conditions and result in the need for additional hospital resources.  Included studies detected an
increase in the CDI incidence in patients with inflammatory bowel disease,  patients with cancer,  those
undergoing surgery,  and even infants.  The results of our systematic review of literature and meta-
analysis emphasize the need to perform C difficile surveillance and direct resources to the prevention of
CDI in order to reduce the incidence across the United States.
Limitations
This systematic literature review has some limitations. First, the results of systematic literature reviews and
meta-analyses are only as valid as the results of the studies evaluated. Most studies included in this
systematic literature review were of moderate-to-low quality and may have overestimated the outcomes.
We need more high-quality studies so that we can accurately determine postinfection LOS, because LOS
before the infection should not be attributed to C difficile.  Second, we included studies that used ICD-9
codes to define CDI. The ICD-9 codes are used for billing purposes and are not ideal for surveillance.
However, a prior meta-analysis  found that the ICD-9 code for C difficile had good sensitivity,
specificity, positive predictive value, and negative predictive value compared with clinical definitions.
Third, we only included studies conducted in the United States and published in English, which limits the
external validity of this research. We used these inclusion criteria because our goal was to evaluate the
burden of CDI in the United States. Future systematic literature reviews should be performed to evaluate
this burden in other countries. Fourth, we found heterogeneity in all LOS-stratified analyses (eAppendix 2
and eTable in the Supplement). We found that the higher-quality studies that used advanced statistical
methods to attempt to account for time-dependent bias found lower CDI-attributable LOS compared with
other studies that did not use advanced methods. In addition, our incidence estimates were derived from
multicenter studies only. Incidence rates in small studies may be variable and subject to bias; thus, this
criterion was established a priori to determine representative incidence rates. From incident cases of CDI
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(36 studies), we were unable to exclude recurrent and multiply recurrent CDI cases if the study did not
exclude those cases. For this meta-analysis, we decided to calculate the incidence rate with studies with a
similar denominator (patient-days), with a result of 8.3 CDI cases per 10 000 patient-days.
Conclusions
Pooled estimates from the currently available literature suggest that C difficile is associated with a large
burden on the US health care system. However, these estimates should be used with caution, and higher-
quality studies should be completed to guide future evaluations of C difficile prevention and treatment
interventions.
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Figure.
Open in a separate window
Literature Search for Articles That Evaluated Incidence and Length of Stay (LOS) Associated With Clostridium
difficile Infection
CINAHL indicates Cumulative Index of Nursing and Allied Health.
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Table 1.
Multicenter Studies (≥5 Sites) That Evaluated Clostridium difficile Infection Incidence
Calculated Using Patient-Days
Open in a separate window
Abbreviations: CDC, Centers for Disease Control and Prevention; HCF, health care facility; HO, hospital onset;
ICD-9, International Classification of Diseases, Ninth Revision; Q, quarter.
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Table 2.
Multicenter Studies (≥5 Sites) That Evaluated Clostridium difficile Infection Incidence
Calculated Using Person-Years
Open in a separate window
Abbreviations: AHRQ, Agency for Healthcare Research and Quality; CDI, Clostridium difficile infection; ICD-9,
International Classification of Diseases, Ninth Revision; VHA, Veterans Health Administration.
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Table 3.
Multicenter Studies (≥5 Sites) That Evaluated Clostridium difficile Infection Incidence Using
Incident Cases
Open in a separate window
Abbreviations: AHRQ, Agency for Healthcare Research and Quality; CDI, Clostridium difficile infection; HO,
hospital onset; ICD-9, International Classification of Diseases, Ninth Revision; NHDS, National Hospital Discharge
Survey; NIS, National Inpatient Sample; VA, Veterans Affairs.
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Table 4.
Length of Stay Associated With Clostridium difficile Infection Among Studies That Used
Appropriate Methods
Open in a separate window
Abbreviations: AHRQ, Agency for Healthcare Research and Quality; CDI, Clostridium difficile infection; HCF, health
care facility; HO, hospital onset; ICD-9, International Classification of Diseases, Ninth Revision; IQR, interquartile
range; LOS, length of stay; NIS, National Inpatient Sample; VA, Veterans’ Affairs.
a
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Methods include propensity score matching or postinfection LOS or matched on preinfection LOS or multistate
modeling.
The Downs and Black scale measures study quality, with a score of 18 or higher indicating higher quality, and a
maximum score of 28 possible.
a
b
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